Skip to main content
Top
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer

Authors: Casina WS Kan, Michael A Hahn, Gregory B Gard, Jayne Maidens, Jung Yoon Huh, Deborah J Marsh, Viive M Howell

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

There is a critical need for improved diagnostic markers for high grade serous epithelial ovarian cancer (SEOC). MicroRNAs are stable in the circulation and may have utility as biomarkers of malignancy. We investigated whether levels of serum microRNA could discriminate women with high-grade SEOC from age matched healthy volunteers.

Methods

To identify microRNA of interest, microRNA expression profiling was performed on 4 SEOC cell lines and normal human ovarian surface epithelial cells. Total RNA was extracted from 500 μL aliquots of serum collected from patients with SEOC (n = 28) and age-matched healthy donors (n = 28). Serum microRNA levels were assessed by quantitative RT-PCR following preamplification.

Results

microRNA (miR)-182, miR-200a, miR-200b and miR-200c were highly overexpressed in the SEOC cell lines relative to normal human ovarian surface epithelial cells and were assessed in RNA extracted from serum as candidate biomarkers. miR-103, miR-92a and miR -638 had relatively invariant expression across all ovarian cell lines, and with small-nucleolar C/D box 48 (RNU48) were assessed in RNA extracted from serum as candidate endogenous normalizers. No correlation between serum levels and age were observed (age range 30-79 years) for any of these microRNA or RNU48. Individually, miR-200a, miR-200b and miR-200c normalized to serum volume and miR-103 were significantly higher in serum of the SEOC cohort (P < 0.05; 0.05; 0.0005 respectively) and in combination, miR-200b + miR-200c normalized to serum volume and miR-103 was the best predictive classifier of SEOC (ROC-AUC = 0.784). This predictive model (miR-200b + miR-200c) was further confirmed by leave one out cross validation (AUC = 0.784).

Conclusions

We identified serum microRNAs able to discriminate patients with high grade SEOC from age-matched healthy controls. The addition of these microRNAs to current testing regimes may improve diagnosis for women with SEOC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tavassoli FA, Devilee P: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 2003, Lyon: IARCPress Tavassoli FA, Devilee P: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 2003, Lyon: IARCPress
2.
3.
go back to reference Dodge JE, Covens AL, Lacchetti C, Elit LM, Le T, Devries-Aboud M, Fung-Kee-Fung M: Preoperative identification of a suspicious adnexal mass: A systematic review and meta-analysis. Gynecol Oncol. 2012, 126 (1): 157-166. 10.1016/j.ygyno.2012.03.048.CrossRefPubMed Dodge JE, Covens AL, Lacchetti C, Elit LM, Le T, Devries-Aboud M, Fung-Kee-Fung M: Preoperative identification of a suspicious adnexal mass: A systematic review and meta-analysis. Gynecol Oncol. 2012, 126 (1): 157-166. 10.1016/j.ygyno.2012.03.048.CrossRefPubMed
4.
go back to reference Drapkin R, von Horsten HH, Lin YF, Mok SC, Crum CP, Welch WR, Hecht JL: Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometriold ovarian carcinomas. Cancer Res. 2005, 65 (6): 2162-2169. 10.1158/0008-5472.CAN-04-3924.CrossRefPubMed Drapkin R, von Horsten HH, Lin YF, Mok SC, Crum CP, Welch WR, Hecht JL: Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometriold ovarian carcinomas. Cancer Res. 2005, 65 (6): 2162-2169. 10.1158/0008-5472.CAN-04-3924.CrossRefPubMed
5.
go back to reference Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S, Podzielinski I, Sokoll L, Smith A, van Nagell JR, Zhang Z: Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol. 2011, 117 (6): 1289-1297. 10.1097/AOG.0b013e31821b5118.CrossRefPubMed Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S, Podzielinski I, Sokoll L, Smith A, van Nagell JR, Zhang Z: Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol. 2011, 117 (6): 1289-1297. 10.1097/AOG.0b013e31821b5118.CrossRefPubMed
6.
go back to reference Ware Miller R, Smith A, DeSimone CP, Seamon L, Goodrich S, Podzielinski I, Sokoll L, van Nagell JR, Zhang Z, Ueland FR: Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol. 2011, 117 (6): 1298-1306. 10.1097/AOG.0b013e31821b1d80.CrossRefPubMed Ware Miller R, Smith A, DeSimone CP, Seamon L, Goodrich S, Podzielinski I, Sokoll L, van Nagell JR, Zhang Z, Ueland FR: Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol. 2011, 117 (6): 1298-1306. 10.1097/AOG.0b013e31821b1d80.CrossRefPubMed
7.
go back to reference Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al: MicroRNA signatures in human ovarian cancer. Cancer Res. 2007, 67 (18): 8699-8707. 10.1158/0008-5472.CAN-07-1936.CrossRefPubMed Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al: MicroRNA signatures in human ovarian cancer. Cancer Res. 2007, 67 (18): 8699-8707. 10.1158/0008-5472.CAN-07-1936.CrossRefPubMed
8.
go back to reference Nam EJ, Yoon HJ, Kim SW, Kim HG, Kim YT, Kim JH, Kim JW, Kim SH: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008, 14 (9): 2690-2695. 10.1158/1078-0432.CCR-07-1731.CrossRefPubMed Nam EJ, Yoon HJ, Kim SW, Kim HG, Kim YT, Kim JH, Kim JW, Kim SH: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008, 14 (9): 2690-2695. 10.1158/1078-0432.CCR-07-1731.CrossRefPubMed
9.
go back to reference Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008, 68 (2): 425-433. 10.1158/0008-5472.CAN-07-2488.CrossRefPubMed Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008, 68 (2): 425-433. 10.1158/0008-5472.CAN-07-2488.CrossRefPubMed
10.
go back to reference Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, Godwin AK, Urban N, Drescher CW, Knudsen BS, Tewari M: Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One. 2009, 4 (4): e5311-10.1371/journal.pone.0005311.CrossRefPubMedPubMedCentral Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, Godwin AK, Urban N, Drescher CW, Knudsen BS, Tewari M: Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One. 2009, 4 (4): e5311-10.1371/journal.pone.0005311.CrossRefPubMedPubMedCentral
11.
go back to reference Wang F, Zheng Z, Guo J, Ding X: Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010, 119 (3): 586-593. 10.1016/j.ygyno.2010.07.021.CrossRefPubMed Wang F, Zheng Z, Guo J, Ding X: Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010, 119 (3): 586-593. 10.1016/j.ygyno.2010.07.021.CrossRefPubMed
12.
go back to reference Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008, 105 (30): 10513-10518. 10.1073/pnas.0804549105.CrossRefPubMedPubMedCentral Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008, 105 (30): 10513-10518. 10.1073/pnas.0804549105.CrossRefPubMedPubMedCentral
13.
go back to reference Cortez MA, Calin GA: MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther. 2009, 9 (6): 703-711. 10.1517/14712590902932889.CrossRefPubMed Cortez MA, Calin GA: MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther. 2009, 9 (6): 703-711. 10.1517/14712590902932889.CrossRefPubMed
14.
go back to reference Chen X, Ba Y, Ma LJ, Cai X, Yin Y, Wang KH, Guo JG, Zhang YJ, Chen JN, Guo X, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18 (10): 997-1006. 10.1038/cr.2008.282.CrossRefPubMed Chen X, Ba Y, Ma LJ, Cai X, Yin Y, Wang KH, Guo JG, Zhang YJ, Chen JN, Guo X, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18 (10): 997-1006. 10.1038/cr.2008.282.CrossRefPubMed
15.
go back to reference Taylor DD, Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008, 110 (1): 13-21. 10.1016/j.ygyno.2008.04.033.CrossRefPubMed Taylor DD, Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008, 110 (1): 13-21. 10.1016/j.ygyno.2008.04.033.CrossRefPubMed
16.
go back to reference Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whangpeng J, Rogan AM, Green WR, Ozols RF: Characterization of a Human Ovarian-Carcinoma Cell-Line (Nih-Ovcar-3) with Androgen and Estrogen-Receptors. Cancer Res. 1983, 43 (11): 5379-5389.PubMed Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whangpeng J, Rogan AM, Green WR, Ozols RF: Characterization of a Human Ovarian-Carcinoma Cell-Line (Nih-Ovcar-3) with Androgen and Estrogen-Receptors. Cancer Res. 1983, 43 (11): 5379-5389.PubMed
17.
go back to reference Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP, Schol DJ, Hilgers J, Leonard RCF, Smyth JF: Characterization and properties of nine human ovarian adenocarcinoma cell-lines. Cancer Res. 1988, 48 (21): 6166-6172.PubMed Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP, Schol DJ, Hilgers J, Leonard RCF, Smyth JF: Characterization and properties of nine human ovarian adenocarcinoma cell-lines. Cancer Res. 1988, 48 (21): 6166-6172.PubMed
18.
go back to reference Conover CA, Hartmann LC, Bradley S, Stalboerger P, Klee GC, Kalli KR, Jenkins RB: Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system. Exp Cell Res. 1998, 238 (2): 439-449. 10.1006/excr.1997.3861.CrossRefPubMed Conover CA, Hartmann LC, Bradley S, Stalboerger P, Klee GC, Kalli KR, Jenkins RB: Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system. Exp Cell Res. 1998, 238 (2): 439-449. 10.1006/excr.1997.3861.CrossRefPubMed
19.
go back to reference Kalli KR, Chen BK, Bale LK, Gernand E, Overgaard MT, Oxvig C, Cliby WA, Conover CA: Pregnancy-associated plasma protein-A (PAPP-A) expression and insulin-like growth factor binding protein-4 protease activity in normal and malignant ovarian surface epithelial cells. Int J Cancer. 2004, 110 (5): 633-640. 10.1002/ijc.20185.CrossRefPubMed Kalli KR, Chen BK, Bale LK, Gernand E, Overgaard MT, Oxvig C, Cliby WA, Conover CA: Pregnancy-associated plasma protein-A (PAPP-A) expression and insulin-like growth factor binding protein-4 protease activity in normal and malignant ovarian surface epithelial cells. Int J Cancer. 2004, 110 (5): 633-640. 10.1002/ijc.20185.CrossRefPubMed
20.
go back to reference Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A, Smyth GK: A comparison of background correction methods for two-colour microarrays. Bioinformatics (Oxford, England). 2007, 23 (20): 2700-2707. 10.1093/bioinformatics/btm412.CrossRef Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A, Smyth GK: A comparison of background correction methods for two-colour microarrays. Bioinformatics (Oxford, England). 2007, 23 (20): 2700-2707. 10.1093/bioinformatics/btm412.CrossRef
21.
go back to reference Smyth GK, Michaud J, Scott HS: Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics (Oxford, England). 2005, 21 (9): 2067-2075. 10.1093/bioinformatics/bti270.CrossRef Smyth GK, Michaud J, Scott HS: Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics (Oxford, England). 2005, 21 (9): 2067-2075. 10.1093/bioinformatics/bti270.CrossRef
22.
go back to reference Smyth GK: Limma: linear models for microarray data. Bioinformatics and computational biology solutions using R and bioconductor. Edited by: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W. 2005, New York: Springer, 397-420.CrossRef Smyth GK: Limma: linear models for microarray data. Bioinformatics and computational biology solutions using R and bioconductor. Edited by: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W. 2005, New York: Springer, 397-420.CrossRef
23.
go back to reference Edgar R, Domrachev M, Lash AE: Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002, 30 (1): 207-210. 10.1093/nar/30.1.207.CrossRefPubMedPubMedCentral Edgar R, Domrachev M, Lash AE: Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002, 30 (1): 207-210. 10.1093/nar/30.1.207.CrossRefPubMedPubMedCentral
24.
go back to reference Wong L, Lee K, Russell I, Chen C: Endogenous controls for real-time quantitation of miRNA using TaqMan® MicroRNA Assays. Applied Biosystems Application Note. 2007, Publication 127AP11-01:available at http://www.lifetechnologies.com Wong L, Lee K, Russell I, Chen C: Endogenous controls for real-time quantitation of miRNA using TaqMan® MicroRNA Assays. Applied Biosystems Application Note. 2007, Publication 127AP11-01:available at http://​www.​lifetechnologies​.​com
25.
go back to reference Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G, Zhang C, et al: Serum MicroRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem. 2012, 58 (3): 610-618. 10.1373/clinchem.2011.172767.CrossRefPubMed Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G, Zhang C, et al: Serum MicroRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem. 2012, 58 (3): 610-618. 10.1373/clinchem.2011.172767.CrossRefPubMed
26.
go back to reference Song J, Bai Z, Han W, Zhang J, Meng H, Bi J, Ma X, Han S, Zhang Z: Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci. 2012, 57 (4): 897-904. 10.1007/s10620-011-1981-7.CrossRefPubMed Song J, Bai Z, Han W, Zhang J, Meng H, Bi J, Ma X, Han S, Zhang Z: Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci. 2012, 57 (4): 897-904. 10.1007/s10620-011-1981-7.CrossRefPubMed
27.
go back to reference Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009, 112 (1): 55-59. 10.1016/j.ygyno.2008.08.036.CrossRefPubMed Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009, 112 (1): 55-59. 10.1016/j.ygyno.2008.08.036.CrossRefPubMed
28.
go back to reference Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, Ohyashiki K, Kuroda M: Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients. PLoS One. 2009, 4 (5): e5532-10.1371/journal.pone.0005532.CrossRefPubMedPubMedCentral Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, Ohyashiki K, Kuroda M: Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients. PLoS One. 2009, 4 (5): e5532-10.1371/journal.pone.0005532.CrossRefPubMedPubMedCentral
29.
go back to reference Peltier HJ, Latham GJ: Normalization of microRNA expression levels in quantitative RT-PCR assays: Identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA-Publ RNA Soc. 2008, 14 (5): 844-852.CrossRef Peltier HJ, Latham GJ: Normalization of microRNA expression levels in quantitative RT-PCR assays: Identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA-Publ RNA Soc. 2008, 14 (5): 844-852.CrossRef
30.
go back to reference Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N: Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol. 2008, 9: 76-10.1186/1471-2199-9-76.CrossRefPubMedPubMedCentral Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N: Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol. 2008, 9: 76-10.1186/1471-2199-9-76.CrossRefPubMedPubMedCentral
31.
go back to reference Reid G, Kirschner MB, van Zandwijk N: Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol. 2011, 80 (2): 193-208. 10.1016/j.critrevonc.2010.11.004.CrossRefPubMed Reid G, Kirschner MB, van Zandwijk N: Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol. 2011, 80 (2): 193-208. 10.1016/j.critrevonc.2010.11.004.CrossRefPubMed
32.
go back to reference Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B: Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One. 2009, 4 (7): e6229-10.1371/journal.pone.0006229.CrossRefPubMedPubMedCentral Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B: Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One. 2009, 4 (7): e6229-10.1371/journal.pone.0006229.CrossRefPubMedPubMedCentral
33.
go back to reference Leskela S, Leandro-Garcia LJ, Mendiola M, Barriuso J, Inglada-Perez L, Munoz I, Martinez-Delgado B, Redondo A, de Santiago J, Robledo M, et al: The miR-200 family controls {beta}-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer. 2011, 18 (1): 85-95.CrossRefPubMed Leskela S, Leandro-Garcia LJ, Mendiola M, Barriuso J, Inglada-Perez L, Munoz I, Martinez-Delgado B, Redondo A, de Santiago J, Robledo M, et al: The miR-200 family controls {beta}-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer. 2011, 18 (1): 85-95.CrossRefPubMed
34.
go back to reference Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O, Nicolas A, Meyniel JP, Cottu P, Sastre-Garau X, et al: miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med. 2011, 17 (12)): 1627-1635.CrossRefPubMed Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O, Nicolas A, Meyniel JP, Cottu P, Sastre-Garau X, et al: miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med. 2011, 17 (12)): 1627-1635.CrossRefPubMed
35.
go back to reference Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN, Wang X: A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol. 2009, 114 (3): 457-46. 10.1016/j.ygyno.2009.05.022.CrossRefPubMed Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN, Wang X: A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol. 2009, 114 (3): 457-46. 10.1016/j.ygyno.2009.05.022.CrossRefPubMed
36.
go back to reference Cochrane DR, Howe EN, Spoelstra NS, Richer JK: Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. Journal of oncology. 2010, 2010: 821717-CrossRefPubMed Cochrane DR, Howe EN, Spoelstra NS, Richer JK: Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. Journal of oncology. 2010, 2010: 821717-CrossRefPubMed
37.
go back to reference Park SM, Gaur AB, Lengyel E, Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008, 22 (7): 894-907. 10.1101/gad.1640608.CrossRefPubMedPubMedCentral Park SM, Gaur AB, Lengyel E, Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008, 22 (7): 894-907. 10.1101/gad.1640608.CrossRefPubMedPubMedCentral
Metadata
Title
Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer
Authors
Casina WS Kan
Michael A Hahn
Gregory B Gard
Jayne Maidens
Jung Yoon Huh
Deborah J Marsh
Viive M Howell
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-627

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine